Literature DB >> 6088420

High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors.

C F LeMaistre, W A Knight.   

Abstract

Toxicity in the form of marrow suppression has hampered the investigation of intensive chemotherapy as it applies to the treatment of solid tumors. The use of autologous marrow rescue to ameliorate protracted aplasia permits the application of high dose chemotherapy to the treatment of solid tumors. We review the theoretical limitations of this technique and present results reported in selected solid tumors. Autologous marrow rescue from intensive chemotherapy is an innovative approach in overcoming the resistence to chemotherapy that is typical of solid tumors. The role of this therapy in the treatment of solid tumors remains to be defined.

Entities:  

Mesh:

Year:  1983        PMID: 6088420     DOI: 10.1007/bf00177416

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  56 in total

1.  Total thoracic supervoltage irradiation followed by the intravenous infusion of stored autogenous marrow.

Authors:  K A NEWTON; J G HUMBLE; C W WILSON; D E PEGG; M E SKINNER
Journal:  Br Med J       Date:  1959-02-28

2.  The effect of the amount of isologous bone marrow injected on the recovery of hematopoietic organs, survival and body weight after lethal irradiation injury in mice.

Authors:  P URSO; C C CONGDON
Journal:  Blood       Date:  1957-03       Impact factor: 22.113

Review 3.  Long-term preservation of cells and tissues: a review.

Authors:  D E Pegg
Journal:  J Clin Pathol       Date:  1976-04       Impact factor: 3.411

4.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

5.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

6.  High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus.

Authors:  R L Souhami; P G Harper; D Linch; C Trask; A H Goldstone; J Tobias; S G Spiro; D M Geddes; J D Richards
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

8.  The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.

Authors:  H M Pinedo; D S Zaharko; J Bull; B A Chabner
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

9.  Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.

Authors:  G L Phillips; J W Fay; G P Herzig; R H Herzig; R S Weiner; S N Wolff; H M Lazarus; C Karanes; W E Ross; B S Kramer
Journal:  Cancer       Date:  1983-11-15       Impact factor: 6.860

10.  High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.

Authors:  J Pritchard; T J McElwain; J Graham-Pole
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.